...New York, N.Y. Dana-Farber Cancer Institute, Boston, Mass. Enterome Bioscience S.A., Paris, France Fimecs Inc., Fujisawa...

...Chem. ; published online July 12, 2017 doi:10.1021/acs.jmedchem.7b00443 CONTACT: Tomohiro Okawa, Takeda Pharmaceutical Co. Ltd., Fujisawa...

...Chem. ; published online June 28, 2017 doi:10.1021/acs.jmedchem.7b00330 CONTACT: Taiji Asami, Takeda Pharmaceutical Co. Ltd., Fujisawa...

...begin operating April 1. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Scohia Pharma Inc. , Fujisawa...

...will spin out eight diabetes, renal and cardiovascular disease candidates into newco Scohia Pharma Inc. (Fujisawa...

...re-upped with FibroGen. The Japanese pharma, created in 2005 through the merger of Yamanouchi and Fujisawa Pharmaceutical Co. Ltd....

...Astellas was formed in 2005 through the merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. Fujisawa...
...exited the cardiovascular space since the company was formed in 2005 from the merger between Fujisawa Pharmaceutical Co. Ltd....

...When Astellas was formed in 2005 via the merger of Yamanouchi Pharmaceutical Co. Ltd. and Fujisawa Pharmaceutical Co. Ltd....

...The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc...
...FDA approved in November to treat cutaneous T cell lymphoma (CTCL). Gloucester in-licensed Istodax from Fujisawa...

...cheaper and faster than big pharma or medium-sized biotech." Gloucester in-licensed Istodax in 2004 from Fujisawa Pharmaceutical Co. Ltd....
...form Astellas Pharma Inc. (Tokyo:4503). "We were in the right place at the right time, Fujisawa...
...for CTCL and PTCL by NCI under a Cooperative Research and Development Agreement (CRADA) with Fujisawa...